ALLK News and Press, Allakos Inc. From 03/07/23

2023-03-07 12:39:41 ET Gainers: ThredUp ( TDUP ) +73% . WW International ( WW ) +49% . Unicycive ( UNCY ) +39% . Protagonist Therapeutics ( PTGX ) +32% . Bionomics ( BNOX ) +28% . Novo Integrated Sciences ( NVOS ) +25% ...

2023-03-07 11:29:42 ET Rebounding from a five-month low in the previous session, Allakos ( NASDAQ: ALLK ) gained ~22% on Tuesday after the clinical-stage biotech announced its Q4 2022 results and Piper Sandler launched its coverage with an Overweight rating. As for the...

2023-03-07 11:28:43 ET Gainers: Unicycive ( UNCY ) +52% . Bionomics ( BNOX ) +49% . Novo Integrated Sciences ( NVOS ) +37% . Protagonist Therapeutics ( PTGX ) +34% . Allakos ( ALLK ) +22% . Losers: Cara ( CARA ) -28...

2023-03-06 17:07:58 ET Allakos press release ( NASDAQ: ALLK ): Q4 GAAP EPS of -$0.50 beats by $0.03 . Allakos ended the fourth quarter of 2022 with $279.8 million in cash, cash equivalents and investments. For further details see: Allakos GAAP EPS of -$0.50 b...

SAN CARLOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results f...

– AK006 is an agonistic antibody that targets the mast cell inhibitory receptor Siglec-6 – – AK006 shows deep mast cell inhibition in pre-clinical studies and was engineered to have antibody-dependent cellular phagocytosis (ADCP) activity – – Alla...

– Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells – – AK007 potently blocks all known ligand interaction with Siglec-10, including the “don’t eat me” signal CD24 – ...

Allakos press release ( NASDAQ: ALLK ): Q3 GAAP EPS of -$0.53 beats by $0.23 . Allakos ended the third quarter of 2022 with $325.3 million in cash, cash equivalents and investments. For further details see: Allakos GAAP EPS of -$0.53 beats by $0.23

SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial...

Summary Results from the phase 2b study, using lirentelimab for the treatment of patients with chronic spontaneous urticaria, are expected in the 2nd half of 2023. Xolair naive CSU cohort of 13 patients started with an average UAS7 score of 18.5 points at baseline and at week 22 d...